Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Population
3119 consecutive in- and out-patients with ECG-documented atrial fibrillation presenting to cardiologists in…
Design
Cohort
Follow-up
1 year
Key result
Despite high oral anticoagulant use (~78%), 1-year mortality remained high at 5.7% among European atrial fibrillation patients, with most deaths being cardiovascular.
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The results show that many European cardiologists prescribe oral anticoagulation for their patients with AF and this is encouraging. But we shouldn't rest on our laurels given that these patients still experience high mortality and morbidity at one year. And we need more information on why so many patients are changing the type of anticoagulation they use.”
“This registry allowed a timely assessment of the clinical scenario in Europe regarding the management of AF. The follow up period of the survey will allow the evaluation of morbidity/mortality over time and also the comparison between outcomes in European regions with different patterns of practice and the dissimilar adherence to ESC guidelines.”
“This is the first study to show better outcomes using the 2012 ESC guidelines on atrial fibrillation. This is novel as the 2012 guidelines – for the first time - focused on the initial identification of 'low risk' patients (that is, CHA2DS2-VASc score 0 in men, 1 in women) who did not need any antithrombotic therapy, following which oral anticoagulation can be offered to those with one or more stroke risk factors.”
Overview
Identifies prognostic factors in AF patients; leaves open whether targeted interventions improve outcomes in high-risk subgroups.
Key Points
- To analyze the management and outcomes of atrial fibrillation patients through a contemporary European registry.
- Enrolled 3119 subjects with AF from 9 ESC countries
- Follow-up at 1 year to assess symptoms, treatment adherence, and outcomes
- Included analysis of predictors for mortality and morbidity
- 76.8% of patients were asymptomatic at follow-up
- 1-year mortality was 5.7%, predominantly cardiovascular causes
- High adherence to oral anticoagulants (∼78%), with 86% of NOAC users remaining on NOAC
Study Design
Type
Cohort (n=3,119)
Multicenter
Yes
Structured PICO
P
Population
3,119 consecutive in- and out-patients with ECG-documented atrial fibrillation from 9 European countries, followed for 1 year.
O
Outcome
Development of symptoms, use of antithrombotic therapy and rate vs. rhythm strategies, as well as determinants of mortality and/or stroke/transient ischaemic attack (TIA)/peripheral embolism during 1-year follow-upcomposite
In a contemporary European registry, despite high adherence to oral anticoagulation, AF patients continue to experience high 1-year mortality and morbidity, particularly from cardiovascular causes and heart failure.
Cite This Study
Lip et al. (2014) conducted a cohort in Atrial Fibrillation (n=3,119). Contemporary management practices was evaluated on 1-year mortality. Despite high oral anticoagulant use (~78%), 1-year mortality remained high at 5.7% among European atrial fibrillation patients, with most deaths being cardiovascular.